Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: Association with cell senescence and tumour-promoting activities of stromal fibroblasts

Cancer Letters

Volumn 179, Issue 1, 2002, Pages 1-14

  Roninson, Igor B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aging; Apoptosis; CDK; Cell cycle; Checkpoints; Chemoprevention; Cyclin; Cyclin dependent kinase inhibitors; DNA damage; Mitosis; Oncogene; p21; Senescence; Tumour stromal interactions

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLINE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; CANCER; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; CELL CYCLE; CHEMOPROPHYLAXIS; ENDOREDUPLICATION; ENZYME INHIBITION; FIBROBLAST; MITOSIS; NONHUMAN; ONCOGENE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; SENESCENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR PROMOTION;

EID: 0037042177     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(01)00847-3     Document Type: Review

References (137)

1. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
2. WAF1, a potential mediator of p53 tumour suppression
3. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. New functional activities for the p21 family of CDK inhibitors
6. Inhibition of cyclin-dependent kinases by p21
7. p21 inhibits thr161 phosphorylation of cdc2 to enforce the G2 DNA damage checkpoint
8. p21(WAF1/Cip1): More than a break to the cell cycle?
9. Waf1/Cip1/Sdi1
10. Waf1/Cip1
11. Reciprocal regulation via protein-protein interaction between c-Myc and p21(cip1/waf1/sdi1) in DNA replication and transcription
12. WAF1/CIP1/SDI1
13. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator
14. A novel transcriptional repression domain mediates p21(WAF1/CIP1) induction of p300 transactivation
15. Waf1/Cip1/Sdi1 on cellular gene expression: Implications for carcinogenesis, senescence, and age-related diseases
16. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism
17. WAF1/CIP1/SDI1 is elevated through a p53-independent pathway by mimosine
18. Transcriptional regulation of the p21 (WAF1/CIP1)gene
19. p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line
20. The biology of replicative senescence
21. The age of cancer
22. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts
23. Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts
24. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
25. DNA topoisomerase inhibitors induce reversible senescence in normal human fibroblasts
26. Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening
27. Absence of cancer-associated changes in human fibroblasts immortalized with telomerase
28. The cat and mouse games that genes, viruses, and cells play
29. A senescence-like phenotype distinguishes tumour cells that undergo terminal proliferation arrest after exposure to anticancer agents
30. Wild-type p53 triggers a rapid senescence program in human tumour cells lacking functional p53
31. Reexpression of the retinoblastoma protein in tumour cells induces senescence and telomerase inhibition
32. Induction of senescence in human malignant glioma cells by p16INK4A
33. Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumour cells lacking functional p53
34. waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumour cells by chemotherapeutic drugs
35. Rapid induction of senescence in human cervical carcinoma cells
36. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
37. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication
38. Identification of CIP-1-associated regulator of cyclin B (CARB), a novel p21-binding protein acting in the G2 phase of the cell cycle
39. Waf1
40. Molecular determinants of terminal growth arrest induced in tumour cells by a chemotherapeutic drug
41. p21 is necessary for the p53-mediated G1 arrest in human cancer cells
42. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
43. Radiation-induced cell cycle arrest compromised by p21 deficiency
44. Requirement for p53 and p21 to sustain G2 arrest after DNA damage
45. Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells
46. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
47. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption
48. CIP1/WAF1 gene in normal diploid human fibroblasts
49. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras
50. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts
51. Tumour susceptibility of p21(Waf1/Cip1)-deficient mice
52. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells
53. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumour growth with distinct tissue specificity
54. Targeted inactivation of the p21(WAF1/CIP1) gene enhances Apc-initiated tumour formation and the tumour-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal
55. WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model
56. Tumourigenic effect of nonfunctional p53 or p21 in mice mutant in the Werner syndrome helicase
57. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice
58. Overexpression of p21 protein in radiation-transformed mouse 10T(1/2) cell clones
59. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma
60. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer
61. Mutations and defective expression of the WAF1 p21 tumour-suppressor gene in malignant melanomas
62. WAF1,CIP1,SDI1 mutant (Arg94→Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases
63. WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas
64. p21WAF1/CIP1 mutants deficient in inhibiting cyclin-dependent kinases (CDKs) can promote assembly of active cyclin D/CDK4(6) complexes in human tumour cells
65. Absence of WAF1 mutations in a variety of human malignancies
66. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations
67. WAF1 mutation is not a predominant alteration in pediatric bone tumours
68. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung
69. Prognostic impact of p21/waf1/cip1 in colorectal cancer
70. WAF1/CIP1 in adenocarcinoma of the uterine cervix: A possible immunohistochemical marker of a favorable prognosis
71. p53, p21 and p27 protein expression in head and neck cancer and their prognostic value
72. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up
73. A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis
74. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer
75. Prognostic and predictive value of p53 and p21 in breast cancer
76. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: An immunohistochemical study
77. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer
78. waf1/cip1 in gastric carcinoma: Lack of inter-relationship or correlation with prognosis
79. Expression of the cell cycle proteins P21, P27, and PRB in clear cell renal cell carcinoma and their prognostic significance
80. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression
81. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
82. WAF1/CIP1 protein expression in primary ovarian cancer
83. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma
84. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus
85. Quantitative p21(waf1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators
86. Modern pathology: Prognostic parameters in squamous cell carcinoma of the esophagus
87. WAF1/Cip1 in human brain tumours
88. WAF1/CIP1 in soft tissue sarcomas: A comparative immunohistochemical study with p53 and Ki-67
89. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer
90. Altered p21(WAF1/CIP1) expression is associated with poor prognosis in extrahepatic bile duct carcinoma
91. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation
92. Waf1/Cip1 expression
93. WAF1/CIP1/SDI1
94. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells
95. Mitotic misregulation and human aging
96. Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis
97. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumour cells
98. Genetic determinants of p53-induced apoptosis and growth arrest
99. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells
100. p21(cip1) rescues human mesenchymal stem cells from apoptosis induced by low-density culture
101. CIP1/WAF1
102. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents
103. Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells
104. Cancer dormancy and cell signaling: Induction of p21(waf1) initiated by membrane IgM engagement increases survival of B lymphoma cells
105. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation
106. E2F1 and p53 are dispensable, whereas p21(Waf1/Cip1) cooperates with Rb to restrict endoreduplication and apoptosis during skeletal myogenesis
107. WAF1/CIP1 expression in normal and neoplastic tissues
108. WAF1/CIP1/SDI1, changes in the expression of p21-regulated genes, and a senescence-like phenotype
109. Mutations truncating the EP300 acetylase in human cancers
110. Senescent fibroblasts promote epithelial cell growth and tumourigenesis: A link between cancer and aging
111. Nucleolar Arf sequesters Mdm2 and activates p53
112. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas
113. Heterotypic signaling between epithelial tumour cells and fibroblasts in carcinoma formation
114. The role of fibroblasts in tumour behavior
115. Fibroblast-mediated acceleration of human epithelial tumour growth in vivo
116. Inhibition of stromal matrix metalloproteases: Effects on breast-tumour promotion by fibroblasts
117. A novel coculture technique demonstrates that normal human prostatic fibroblasts contribute to tumour formation of LNCaP cells by retarding cell death
118. Fibroblasts are critical determinants in prostatic cancer growth and dissemination
119. Carcinoma-associated fibroblasts direct tumour progression of initiated human prostatic epithelium
120. Paracrine induction of angiogenesis in vitro by Swiss 3T3 fibroblasts
121. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts
122. Transforming growth factor-beta1 promotes the morphological and functional differentiation of the myofibroblast
123. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumours and to lymph node metastases of human mammary carcinoma
124. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta
125. Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts
126. Irradiated mammary gland stroma promotes the expression of tumourigenic potential by unirradiated epithelial cells
127. Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light
128. The p66shc adaptor protein controls oxidative stress response and life span in mammals
129. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development
130. The lack of a functional p21(WAF1/CIP1) gene ameliorates progression to chronic renal failure
131. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy
132. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells
133. Increased gene expression of Alzheimer disease beta-amyloid precursor protein in senescent cultured fibroblasts
134. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
135. Inhibition of NF-kappa B by sodium salicylate and aspirin
136. Sulindac inhibits activation of the NF-kappaB pathway
137. Cyclooxygenase-2: A novel target for cancer chemotherapy?